Gene Logic Shares Tumble 15.5 Percent on Q3 Revenue Decline, Preclinical Divestiture | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Gene Logic were down 15.47 percent, or $.30, at $1.64 in midday trading after the company this morning said third-quarter revenue slid 39 percent, and that it plans to sell its preclinical services division.
 
After stating in September that the preclinical services segment would not be put on the block, today Gene Logic said it has hired an investment firm to help it divest the unit, and is currently in discussions for the sale.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.